IP Verse

Combination Immunotherapy For The Treatment Of Cancer - EP2482849

The patent EP2482849 was granted to Board OF Regents on Jun 6, 2018. The application was originally filed on Sep 30, 2010 under application number EP10821297A. The patent is currently recorded with a legal status of "Revoked".

EP2482849

BOARD OF REGENTS
Application Number
EP10821297A
Filing Date
Sep 30, 2010
Status
Revoked
May 8, 2023
Grant Date
Jun 6, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GLAXOSMITHKLINEMar 6, 2019KIM -
KYMABMar 6, 2019LEONARD -

Patent Citations (21) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2005003506
DESCRIPTIONUS5935934
DESCRIPTIONUS5989910
DESCRIPTIONUS6004941
DESCRIPTIONUS6015709
DESCRIPTIONUS6051227
INTERNATIONAL-SEARCH-REPORTUS2003124149
INTERNATIONAL-SEARCH-REPORTUS2005085433
INTERNATIONAL-SEARCH-REPORTUS2007122378
INTERNATIONAL-SEARCH-REPORTUS2008069795
OPPOSITIONUS2003124149
OPPOSITIONUS2009055944
OPPOSITIONWO0114424
OPPOSITIONWO2005103086
OPPOSITIONWO2006133396
OPPOSITIONWO2007113648
OPPOSITIONWO2008137915
OPPOSITIONWO2010077634
OPPOSITIONWO2016120789
OPPOSITIONWO2016154177
SEARCHWO2007113648

Non-Patent Literature (NPL) Citations (60) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- SHENG YAO ET AL, "B7-H2 Is a Costimulatory Ligand for CD28 in Human", IMMUNITY, CELL PRESS, US, vol. 34, no. 5, doi:10.1016/J.IMMUNI.2011.03.014, ISSN 1074-7613, (20110318), pages 729 - 740, (20110323), XP028218515
EXAMINATION- MANDY L. FORD ET AL, "Targeting co-stimulatory pathways: transplantation and autoimmunity", NATURE REVIEWS NEPHROLOGY, (20131008), vol. 10, no. 1, doi:10.1038/nrneph.2013.183, ISSN 1759-5061, pages 14 - 24, XP055197672
EXAMINATION- WARD ROBERT C ET AL, "Targeting costimulatory pathways for tumor immunotherapy", INTERNATIONAL REVIEWS OF IMMUNOLOGY, HARWOOD ACADEMIC PUBLISHERS, LONDON, GB, (20070501), vol. 26, no. 3-4, doi:10.1080/08830180701365941, ISSN 0883-0185, pages 161 - 196, XP009170473
EXAMINATION- VAN ELSAS A ET AL, "Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTL-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, (19990802), vol. 190, no. 3, doi:10.1084/JEM.190.3.355, ISSN 0022-1007, pages 355 - 366, XP002966969
EXAMINATION- GREENWALD REBECCA J ET AL, "The B7 family revisited", ANNUAL REVIEW OF IMMUNOLOGY 2005,, (20050119), vol. 23, doi:10.1146/ANNUREV.IMMUNOL.23.021704.115611, pages 515 - 548, XP002481408
EXAMINATION- Mary E. Keir ET AL, "PD-1 and Its Ligands in Tolerance and Immunity", ANNUAL REVIEW OF IMMUNOLOGY., US, (20080102), vol. 26, no. 1, doi:10.1146/annurev.immunol.26.021607.090331, ISSN 0732-0582, pages 677 - 704, XP055099324
INTERNATIONAL-SEARCH-REPORT- XINGXING ZANG ET AL, "The B7 family and cancer therapy: costimulation and coinhibition", CLINICAL CANCER RESEARCH, (2007), vol. 13, no. 18, pages 5271 - 5279, XP008161228
OPPOSITION- Anonymous, "Jounce Therapeutics Announces Update on Vopratelimab Program", Jounce Therapeutics, (20201102), pages 1 - 2, XP055782377-
OPPOSITION- "Anti-ICOS Monoclonal Antibody MEDl-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma NCT02520791", ClinicalTrials.gov, (20150813), pages 1 - 12, URL: https://clinicaltrials.gov/ct2/show/NCT02520791, XP055571916-
OPPOSITION- Briskin Michael J, "Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics", SITC 30th Anniversary Annual Meeting (2015): Late Breaking Abstract Session II, (20151108), pages 1 - 22, XP055782379-
OPPOSITION- DENG, ZHONG-BIN et al., "An Agonist Human ICOS Monoclonal Antibody that Induces T Cell Activation and Inhibits Proliferation of a Myeloma Cell Line", Hybridoma and Hybridomics, (20040000), vol. 23, no. 3, pages 176 - 182, XP002657735-
OPPOSITION- Dynal CD 4 T cell isolation kit manual-
OPPOSITION- "Enhancing Immunotherpay: The Race to Make "Cold" Tumors "Hot"", Dana Farber Cancer Institute, (20180606), URL: https://blog.dana-farber.org/insight/2018/06/enhancing- immunotherapy-race-make-cold-tumors-hot, XP055572043-
OPPOSITION- MCADAM et al., "Mouse Inducible Costimulatory Molecule (ICOS) Expression Is Enhanced by CD 28 Costimulation and Regulates Differentiation of CD 4+ T Cells", J. Immunol., (20000000), vol. 165, pages 5035 - 5040, XP002966701-
OPPOSITION- Nick Paul Taylor, "AstraZeneca's tremelimumab fails another phase 3 cancer trial", FierceBiotech, (20181207), URL: https://www.fiercebiotech.com/biotech/astrazeneca-stremelimumab-fails-another-phase-3-cancer-trial, XP055571946-
OPPOSITION- "Nivolumab for Head and Neck Cancer", NCI report, (20161201), XP55782373-
OPPOSITION- Shirakawa, "The Current Status of Adenovirus-based Cancer Gene Therapy", Mol. Cells, (20080506), vol. 25, no. 4, pages 462 - 466, XP055620959-
OPPOSITION- Study report on the ability of KY1044 to induce release of I FNy from human T cells-
OPPOSITION- Trehu Beth, Et Al, "Lessons learned from a clinical trial targeting ICOS", Keystone Symposium, Jounce Therapeutics, (20190312), pages 1 - 33, XP055782371-
OPPOSITION- Yu Jong W, Et Al, "Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments Funding: GlaxoSmithKline provided support in the form of salaries for authors JWY", plos One, (20181102), vol. 13, no. 11, pages 1 - 27, XP055782390-
OPPOSITION- BEIER et al., "Induction, binding specificity and function of human ICOS", Eur. J. Immunol., (20000000), vol. 30, pages 3707 - 3717, XP055571964
OPPOSITION- SIMPSON, TYLER et al., "Regulation of CD 4 T cell activation and effector function by inducible costimator", Current Opinion in Immunology, (20100000), vol. 22, pages 326 - 332, XP027072474
OPPOSITION- van Berkel & Oosterwegel, "CD 28 and ICOS: Similar or separate costimulators of T cells", Immunol. Lett., (20060000), vol. 105, pages 115 - 122, XP005480645
OPPOSITION- ROBERT EAGER et al., "GM-CSF Gene-Transduced Tumor Vaccines", Molecular Therapy, (20050000), vol. 12, no. 1, pages 18 - 27, XP004925150
OPPOSITION- DENG, RUISHU et al., "Extrafollicular CD 4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus- host disease", Nature Communications, (20170000), vol. 8, no. 1, page 117, XP055571922
OPPOSITION- GALON et al., "Approaches to treat immune hot, altered and cold tumours with combination immunotherapies", Nat. Drug. Disc., (20190000), vol. 18, no. 3, pages 197 - 218, XP036715681
OPPOSITION- BINNEWIES et al., "Understanding the tumor immune microenvironment (TME) for effective therapy", Nature Medicine, (20180000), vol. 24, no. 5, pages 541 - 550, XP036513461
OPPOSITION- PUHLER et al., "Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes", Gene Ther., (20080117), vol. 15, no. 5, doi:10.1038/SJ.GT.3303095, pages 371 - 83, XP002616517
OPPOSITION- HAMADA et al., "Carrier Cell -mediated Delivery of a Replication-competent Adenovirus for Cancer Gene Therapy", Mol. Ther., (20070601), vol. 15, no. 6, pages 1121 - 1128, XP055620966
OPPOSITION- Robert L. Ferris et al, "Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck", The New England journal of medicine, Massachusetts Medical Society, US, US, (20161110), vol. 375, no. 19, doi:10.1056/NEJMoa1602252, ISSN 0028-4793, pages 1856 - 1867, XP055727440
OPPOSITION- CURRAN, MICHAEL et al., "PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma Tumors", PNAS, (20100301), vol. 107, no. 9, pages 4275 - 4280, XP055067204
OPPOSITION- IWAI et al., "Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade", PNAS, (20020000), vol. 99, no. 19, pages 12293 - 12297, XP055572034
OPPOSITION- LIU A Y., ET AL., "CHIMERIC MOUSE-HUMAN IGG1 ANTIBODY THAT CAN MEDIATE LYSIS OF CANCER CELLS.", Proceedings of the National Academy of Sciences, National Academy of Sciences, (19870501), vol. 84., doi:10.1073/pnas.84.10.3439, ISSN 0027-8424, pages 3439 - 3443., XP000939047
OPPOSITION- DRANOFF et al., "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity", PNAS, (19930415), vol. 90, doi:10.1073/pnas.90.8.3539, pages 3539 - 3543, XP001117909
OPPOSITION- ROBERT C. WARD et al., "Targeting costimulatory pathways for tumor immunotherapy", International Reviews of Immunology, (20070000), vol. 26, no. 3-4, pages 161 - 196, XP009170473
OPPOSITION- VAN ELSAS et al., "Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTL-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors", J. Exp. Med., (19990000), vol. 190, no. 3, pages 355 - 366, XP002966969
OPPOSITION- LISTON et al., "Dicer-dependent microRNA pathway safeguards regulatory T cell function", J. Exp. Med., (20080000), vol. 205, no. 9, pages 1993 - 2004, XP055571996
OPPOSITION- DRIESSENS, GREGORY et al., "Costimulatory and coinhibitory receptors in anti-tumor immunity", Immunol Rev., (20090000), vol. 229, pages 126 - 144, XP055571905
OPPOSITION- KEIR et al., "PD1 and Its Ligands in Tolerance and Immunity", Annu. Rev. Immunol., (20080102), vol. 26, doi:10.1146/annurev.immunol.26.021607.090331, pages 677 - 704, XP055099324
OPPOSITION- CAMUS et al., "Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence", Cancer Res, (20090000), vol. 69, no. 6, pages 2685 - 2693, XP055571972
OPPOSITION- MARTIN-OROZCO, NATALIA et al., "Melanoma Cells Express ICOS Ligand to Promote the Activation and Expansion of T- Regulatory Cells", American Association for Cancer Research, (20100000), vol. 70, pages 9581 - 9590, XP055571958
OPPOSITION- QUEZADA, SERGIO et al., "CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells", The Journal of Clinical Investigation, (20060703), vol. 116, no. 7, pages 1935 - 1945, XP002556462
OPPOSITION- GERRITSEN, W et al., "A dose-escalation trial of GM-CSF- gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody", Journal of Clinical Oncology, (20060000), URL: https://ascopubs.org/doi/abs/10.1200/jco.2006.24.18_suppl.2500, XP055571934
OPPOSITION- BEER et al., "Randomized, Double-Blind, Phase III Trial of Ipilimimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naieve Castration-Resistant Prostate Cancer", Journal of Clinical Oncology, (20170000), vol. 35, no. 1, pages 40 - 47, XP055571943
OPPOSITION- Hanson Amanda, Et Al, "ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models", PLOS ONE, (20200924), vol. 15, no. 9, doi:10.1371/journal.pone.0239595, pages 1 - 21, XP055782381
OPPOSITION- Nemunaitis, "Vaccines in cancer: GVAXO, a GM-CSF gene vaccine", Expert. Rev. Vaccines, (20050600), vol. 4, no. 3, pages 259 - 274, XP055620971
OPPOSITION- INMAN, BRANT A. et al., "Costimation, Coinhibition and Cancer", Current Cancer Drug Targets, (20070000), vol. 7, pages 15 - 30, XP055068424
OPPOSITION- ODEGARD et al., "ICOS Controls Effector Function but Not Trafficking Receptor Expression of Kidney-Infiltrating Effector T Cells in Murine Lupus", J Immunol, (20090000), vol. 182, pages 4076 - 4084, XP055571987
OPPOSITION- CURRIE, ANDREW et al., "Dual Control of Antitumor CD 8 T cells through the Programmed Death-1/Programmed Death- Ligand 1 Pathway and Immunosuppresive CD 4 T Cells ; Regulation and Counterregulation", The Journal of Immunology, (20090000), pages 7898 - 7908, XP055571941
OPPOSITION- HODGE et al., "Multiple Costimulatory Modalities Enhance CTL Avidity", J. Immunol., (20050515), vol. 174, pages 5994 - 6004, XP055620979
OPPOSITION- BURMEISTER, YVONNE et al., "ICOS Controls the Pool Size of Effector-Memory and Regulatory T Cells", The Journal of Immunology, (20080000), vol. 180, pages 774 - 782, XP055571920
OPPOSITION- STRAUSS, LAURA et al., "Expression of ICOS on Human Melanoma-Infiltrating CD 4+ CD 25 high Foxp3+ T Regulatory Cells: Implications and Impact on Tumor-Mediated Immune Suppression", The Journal of Immunology, (20080000), vol. 180, no. 5, pages 2967 - 2980, XP055571950
SEARCH- DENG ZHONG-BIN ET AL, "An agonist human ICOS monoclonal antibody that induces T cell activation and inhibits proliferation of a myeloma cell line", HYBRIDOMA AND HYBRIDOMICS, MARY ANN LIEBERT, NEW YORK, NY, US, (20040601), vol. 23, no. 3, ISSN 1536-8599, pages 176 - 182, XP002657735 [A] 1-15 * abstract *-
SEARCH- Jeffrey J Wallin ET AL, "Enhancement of CD81 T Cell Responses by ICOS/B7h Costimulation", J Immunol, (20010701), URL: http://www.jimmunol.org/content/167/1/132.full.pdf#page=1&view=FitH, (20130626), XP055068448 [A] 1-15 * abstract *-
SEARCH- PEGGS K S ET AL, "Principles and use of anti-CTLA4 antibody in human cancer immunotherapy", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 18, no. 2, ISSN 0952-7915, (20060401), pages 206 - 213, (20060401), XP027932780 [A] 1-15 * the whole document *-
SEARCH- GULSHAN ARA ET AL, "Potent activity of soluble B7RP-1-Fc in therapy of murine tumors in syngeneic hosts", INTERNATIONAL JOURNAL OF CANCER, (20030210), vol. 103, no. 4, doi:10.1002/ijc.10831, ISSN 0020-7136, pages 501 - 507, XP055067328 [A] 1-15 * abstract *
SEARCH- BRIDGET VESOSKY ET AL, "Modulation of costimulation to enhance tumor immunity", CANCER IMMUNOLOGY, IMMUNOTHERAPY, (20031101), vol. 52, no. 11, doi:10.1007/s00262-003-0424-5, ISSN 0340-7004, pages 663 - 669, XP055068412 [A] 1-15 * the whole document *
SEARCH- KRYSTYNA ZUBEREK ET AL, "Comparable in vivo efficacy of CD28/B7, ICOS/GL50, and ICOS/GL50B costimulatory pathways in murine tumor models: IFN[gamma]-dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL", CELLULAR IMMUNOLOGY, (20030901), vol. 225, no. 1, doi:10.1016/j.cellimm.2003.09.002, ISSN 0008-8749, pages 53 - 63, XP055068449 [Y] 1-15 * abstract * * page 55, column r, paragraph 3 * * page 55, column r, paragraph 4 - page 56, column r, paragraph 1 * * page 62, column l, paragraph 2 *
SEARCH- B A Inman ET AL, "Costimulation, Coinhibition and Cancer", Current Cancer Drug Targets, (20070101), pages 15 - 30, URL: http://www.eurekaselect.com/58737/article, (20130626), XP055068424 [A] 1-15 * the whole document *
SEARCH- M E Van Berkel ET AL, "ICOS contributes to T cell expansion in CTLA-4 deficient mice.", J Immunol., (20050701), pages 182 - 188, URL: http://www.jimmunol.org/content/175/1/182.full.pdf#page=1&view=FitH, (20130626), XP055068410 [A] 1-15 * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents